Skip to main content
    I

    IGC Pharma, Inc. (IGC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.19
    +0.00 (+0.11%)

    Market Cap: $20.54M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    IGC Pharma, Inc. (IGC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    IGC Pharma reported revenue of $1.19M for the fiscal year ended Mar 31, 2026, down 6.7% from the year before. That year, net income was -$6.55M with a net margin of -552.1%, operating cash flow was -$5.94M and free cash flow was -$6.11M. The quarter ended Sep 30, 2026 had revenue of $328.00K and net income of -$2.05M.

    Revenue and Margins

    Over the 9 years to Mar 2026, revenue grew from $580.37K, a compound annual rate of 8.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$1.19M-6.7%29.7%-860.3%-552.1%
    Mar 2025$1.27M-5.5%48.7%-585.8%-560.3%
    Mar 2024$1.34M+47.6%54.5%-728.5%-966.5%
    Mar 2023$911.00K+129.5%48.5%-1270.1%-1263.0%
    Mar 2022$397.00K+39600.0%48.9%-3886.1%-3782.4%
    Mar 2021$1.00K-100.0%11300.0%-872400.0%-881100.0%
    Mar 2020$4.07M-20.4%2.8%-168.6%-179.6%
    Mar 2019$5.12M+133.3%2.6%-90.8%-80.1%
    Mar 2018$2.19M+277.9%3.7%-81.6%-81.4%
    Mar 2017$580.37KN/A37.6%-353.8%-319.3%
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue$1.19M$1.27M$1.34M$911.00K$397.00K$1.00K$4.07M$5.12M$2.19M$580.37K
    Cost of revenue$834.00K$652.00K$612.00K$469.00K$203.00K$785.00K$3.96M$4.98M$2.11M$362.13K
    Gross profit$352.00K$619.00K$733.00K$442.00K$194.00K$113.00K$115.00K$132.00K$82.00K$218.24K
    Research and development$5.19M$3.65M$3.77M$3.46M$2.33M$929.00K$1.01M$1.26M$137.00K$0
    Operating income-$10.20M-$7.45M-$9.80M-$11.57M-$15.43M-$8.72M-$6.86M-$4.64M-$1.79M-$2.05M
    Net income-$6.55M-$7.12M-$13.00M-$11.51M-$15.02M-$8.81M-$7.32M-$4.10M-$1.79M-$1.85M
    EBITDA-$6.22M-$6.50M-$9.02M-$10.85M-$14.32M-$8.16M-$6.38M-$4.04M-$1.77M-$1.44M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$328.00K$265.00K$317.00K$350.00K$191.00K$328.00K$330.00K$257.00K$412.00K$330.00K$295.00K$204.00K
    Gross profit$61.00K$48.00K$55.00K$44.00K$99.00K$154.00K$154.00K$104.00K$198.00K$154.00K$171.00K$133.00K
    Operating income-$1.93M-$2.78M-$2.46M-$2.94M-$2.90M-$1.91M-$1.41M-$1.88M-$1.76M-$1.41M-$2.17M-$3.00M
    Net income-$2.05M-$2.94M-$2.40M-$726.00K-$1.82M-$1.60M-$1.20M-$1.83M-$1.72M-$1.20M-$2.88M-$5.59M
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, total debt of $866.00K exceeded cash and equivalents by $659.00K.

    Annual

    Line itemMar 2026Dec 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
    Total assets$9.19M$9.71M$9.71M$9.90M$17.18M$26.83M$35.87M$28.98M$34.47M$10.85M
    Current assets$1.15M$1.79M$1.79M$3.71M$6.47M$15.11M$23.52M$17.76M$26.72M$3.21M
    Cash and equivalents$207.00K$900.00K$900.00K$1.20M$3.20M$10.46M$14.55M$7.26M$25.61M$1.66M
    Total liabilities$3.06M$2.29M$2.29M$2.58M$2.27M$2.94M$3.06M$2.45M$893.00K$2.79M
    Short-term debt$735.00K$180.00K$180.00K$251.00K$269.00K$126.00K$304.00K$50.00K$50.00K$1.80M
    Long-term debt$131.00K$131.00K$131.00K$137.00K$141.00K$144.00K$276.00K$0$0$427.00K
    Shareholder equity$6.12M$7.42M$7.42M$7.32M$14.91M$23.89M$32.80M$26.54M$33.57M$8.06M
    Fiscal years ended Mar 2018 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$9.73M$9.50M$9.19M$9.71M$9.74M$9.19M$8.75M$9.08M$10.37M$10.59M$9.90M$11.26M
    Total liabilities$3.23M$3.36M$3.06M$2.29M$1.65M$3.06M$2.42M$2.82M$2.99M$2.71M$2.58M$2.21M
    Cash and equivalents$377.00K$331.00K$207.00K$900.00K$1.10M$207.00K$405.00K$470.00K$1.55M$1.82M$1.20M$1.38M
    Shareholder equity$6.50M$6.13M$6.12M$7.42M$8.09M$6.12M$6.33M$6.26M$7.38M$7.88M$7.32M$9.05M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow-$5.94M-$4.79M-$5.20M-$7.05M-$7.46M-$10.80M-$8.68M-$3.33M-$1.93M-$1.39M
    Capital expenditures$164.00K$112.00K$138.00K$310.00K$236.00K$1.47M$4.39M$15.00K$136.00K$145.68K
    Free cash flow-$6.11M-$4.91M-$5.34M-$7.36M-$7.70M-$12.27M-$13.07M-$3.35M-$2.07M-$1.54M
    Share repurchasesN/AN/AN/AN/AN/AN/A$59.00KN/AN/AN/A
    Investing cash flow-$192.00K-$442.00K-$317.00K-$235.00K-$742.00K$3.39M-$9.55M-$260.00K-$657.00K-$241.35K
    Financing cash flow$5.93M$4.45M$3.52M$100.00K$4.14M$14.69M-$59.00K$27.60M$3.71M$707.56K
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.42M-$1.35M-$1.22M-$1.22M-$2.09M-$1.41M-$730.00K-$1.32M-$1.41M-$730.00K-$526.00K-$1.59M
    Capital expendituresN/A$5.00K$1.00K$12.00K$29.00K$8.00K$18.00K$27.00K$8.00K$18.00K$15.00K$68.00K
    Free cash flowN/A-$1.35M-$1.22M-$1.24M-$2.12M-$1.42M-$748.00K-$1.34M-$1.42M-$748.00K-$541.00K-$1.66M
    Last 12 quarters

    Frequently Asked Questions About IGC

    What is IGC Pharma's annual revenue?

    IGC Pharma reported revenue of $1.19M for the fiscal year ended Mar 31, 2026.

    How fast is IGC Pharma's revenue growing?

    Revenue was down 6.7% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 9.2%.

    Is IGC Pharma profitable?

    No. IGC Pharma reported net income of -$6.55M for the fiscal year ended Mar 31, 2026, with a net margin of -552.1%.

    How much free cash flow does IGC generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$5.94M minus capital expenditures of $164.00K produced free cash flow of -$6.11M.

    How much debt does IGC Pharma have?

    The balance sheet dated Mar 31, 2026 reported long-term debt of $131.00K, short-term debt of $735.00K and cash and equivalents of $207.00K.